AVANIR Pharmaceuticals Invites Investors to Its Second Quarter Conference Call on Monday, May 8, 2006.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- AVANIR Pharmaceuticals (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :AVNR AVNR Atrioventricular Nodal Reentry ) will webcast its quarterly conference call on Monday, May 8, 2006, at 1:30 p.m. Pacific/4:30 p.m. Eastern. The call will be webcast live through AVANIR's corporate website at www.avanir.com and will feature Eric Brandt, President and Chief Executive Officer, and Gregory P. Hanson, Vice President and Chief Financial Officer. A press release announcing the second quarter 2006 financial results will be released prior to the conference call the same day. It is recommended that you go to AVANIR's website at least 10 minutes in advance of the webcast to download any applicable software. For those who cannot listen to the live broadcast, the online replay will be available for 30 days, and a phone replay will be available through May 15, 2006, by dialing 800-642-1687 (domestic) and 706-645-9291 (international) and entering the passcode 8238299. About AVANIR AVANIR Pharmaceuticals is focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious diseases infectious diseases: see communicable diseases. . AVANIR previously announced positive results in the second of two required Phase III clinical trials of Neurodex(TM), an investigational new drug for the treatment of involuntary emotional expression disorder (IEED IEED Involuntary Emotional Expression Disorder ). Additionally, AVANIR has initiated a Phase III clinical trial for Neurodex as a potential treatment in patients with diabetic neuropathic pain, a second indication for Neurodex. AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd., for the treatment of inflammatory disease Noun 1. inflammatory disease - a disease characterized by inflammation disease - an impairment of health or a condition of abnormal functioning NEC, necrotizing enterocolitis - an acute inflammatory disease occurring in the intestines of premature infants; , and AstraZeneca, for the treatment of cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . The Company's first commercialized product, "abreva(R)," is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion